Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 2/2023

22.10.2022 | Original Article

Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy

verfasst von: Annie Ogasawara, James R. Kiefer, Herman Gill, Eugene Chiang, Shravan Sriraman, Gregory Z. Ferl, James Ziai, Sandra Sanabria Bohorquez, Sebastian Guelman, Xiangdan Wang, Jihong Yang, Minh Michael Phan, Van Nguyen, Shan Chung, Christine Yu, Jeff Tinianow, Stijn Jan Hein Waaijer, Alex De Crespigny, Jan Marik, C. Andrew Boswell, Tanja Zabka, Karin Staflin, Simon-Peter Williams

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

ZED8 is a novel monovalent antibody labeled with zirconium-89 for the molecular imaging of CD8. This work describes nonclinical studies performed in part to provide rationale for and to inform expectations in the early clinical development of ZED8, such as in the studies outlined in clinical trial registry NCT04029181 [1].

Methods

Surface plasmon resonance, X-ray crystallography, and flow cytometry were used to characterize the ZED8-CD8 binding interaction, its specificity, and its impact on T cell function. Immuno-PET with ZED8 was assessed in huCD8+ tumor-bearing mice and in non-human primates. Plasma antibody levels were measured by ELISA to determine pharmacokinetic parameters, and OLINDA 1.0 was used to estimate radiation dosimetry from image-derived biodistribution data.

Results

ZED8 selectively binds to human CD8α at a binding site approximately 9 Å from that of MHCI making mutual interference unlikely. The equilibrium dissociation constant (KD) is 5 nM. ZED8 binds to cynomolgus CD8 with reduced affinity (66 nM) but it has no measurable affinity for rat or mouse CD8. In a series of lymphoma xenografts, ZED8 imaging was able to identify different CD8 levels concordant with flow cytometry. In cynomolgus monkeys with tool compound 89Zr-aCD8v17, lymph nodes were conspicuous by imaging 24 h post-injection, and the pharmacokinetics suggested a flat-fixed first-in-human dose of 4 mg per subject. The whole-body effective dose for an adult human was estimated to be 0.48 mSv/MBq, comparable to existing 89Zr immuno-PET reagents.

Conclusion

89Zr immuno-PET with ZED8 appears to be a promising biomarker of tissue CD8 levels suitable for clinical evaluation in cancer patients eligible for immunotherapy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat de Vries EG. ImmunoPET with an anti-CD8 imaging agent. www.clinicaltrials.gov; July 23, 2019. p. NCT04029181. de Vries EG. ImmunoPET with an anti-CD8 imaging agent. www.clinicaltrials.gov; July 23, 2019. p. NCT04029181.
4.
Zurück zum Zitat Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109:2705–13. https://doi.org/10.1038/bjc.2013.634. Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109:2705–13. https://​doi.​org/​10.​1038/​bjc.​2013.​634.
8.
Zurück zum Zitat Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, et al. CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment. Clin Cancer Res. 2018;24:3036–45. https://doi.org/10.1158/1078-0432.CCR-17-2257. Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, et al. CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment. Clin Cancer Res. 2018;24:3036–45. https://​doi.​org/​10.​1158/​1078-0432.​CCR-17-2257.
9.
Zurück zum Zitat Ledys F, Klopfenstein Q, Truntzer C, Arnould L, Vincent J, Bengrine L, et al. RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer. J Immunother Cancer. 2018;6:123. https://doi.org/10.1186/s40425-018-0438-3. Ledys F, Klopfenstein Q, Truntzer C, Arnould L, Vincent J, Bengrine L, et al. RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer. J Immunother Cancer. 2018;6:123. https://​doi.​org/​10.​1186/​s40425-018-0438-3.
16.
Zurück zum Zitat Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol. 2016;27:619–24. https://doi.org/10.1093/annonc/mdv577.CrossRef Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol. 2016;27:619–24. https://​doi.​org/​10.​1093/​annonc/​mdv577.CrossRef
18.
Zurück zum Zitat Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O’Donoghue JA, et al. First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting. J Nucl Med. 2020;61:512–9. https://doi.org/10.2967/jnumed.119.229781.CrossRef Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O’Donoghue JA, et al. First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting. J Nucl Med. 2020;61:512–9. https://​doi.​org/​10.​2967/​jnumed.​119.​229781.CrossRef
19.
21.
Zurück zum Zitat Clement M, Ladell K, Ekeruche-Makinde J, Miles JJ, Edwards ES, Dolton G, et al. Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. J Immunol. 2011;187:654–63. https://doi.org/10.4049/jimmunol.1003941. Clement M, Ladell K, Ekeruche-Makinde J, Miles JJ, Edwards ES, Dolton G, et al. Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. J Immunol. 2011;187:654–63. https://​doi.​org/​10.​4049/​jimmunol.​1003941.
28.
29.
33.
Zurück zum Zitat Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.
48.
Zurück zum Zitat Vugts DJ, Klaver C, Sewing C, Poot AJ, Adamzek K, Huegli S, et al. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET. Eur J Nucl Med Mol Imaging. 2017;44:286–95. https://doi.org/10.1007/s00259-016-3499-x.CrossRef Vugts DJ, Klaver C, Sewing C, Poot AJ, Adamzek K, Huegli S, et al. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET. Eur J Nucl Med Mol Imaging. 2017;44:286–95. https://​doi.​org/​10.​1007/​s00259-016-3499-x.CrossRef
49.
53.
56.
Zurück zum Zitat Omidvari N, Jones T, Price P, Sen F, Shacklett B, Cohen S, et al. Total-body imaging of CD8+ T cells in patients recovering from COVID-19. A pilot study using uEXPLORER total-body PET. Journal of Nuclear Medicine. 2022;63. Omidvari N, Jones T, Price P, Sen F, Shacklett B, Cohen S, et al. Total-body imaging of CD8+ T cells in patients recovering from COVID-19. A pilot study using uEXPLORER total-body PET. Journal of Nuclear Medicine. 2022;63.
Metadaten
Titel
Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
verfasst von
Annie Ogasawara
James R. Kiefer
Herman Gill
Eugene Chiang
Shravan Sriraman
Gregory Z. Ferl
James Ziai
Sandra Sanabria Bohorquez
Sebastian Guelman
Xiangdan Wang
Jihong Yang
Minh Michael Phan
Van Nguyen
Shan Chung
Christine Yu
Jeff Tinianow
Stijn Jan Hein Waaijer
Alex De Crespigny
Jan Marik
C. Andrew Boswell
Tanja Zabka
Karin Staflin
Simon-Peter Williams
Publikationsdatum
22.10.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2023
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-022-05968-6

Weitere Artikel der Ausgabe 2/2023

European Journal of Nuclear Medicine and Molecular Imaging 2/2023 Zur Ausgabe